We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Abbott Diagnostics- Hematology Division


Fluidigm Corporation focuses on the most pressing needs in translational and clinical research, including cancer, imm... read more Featured Products: More products

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Biomarkers Associated with Major Bleeding in Patients with Atrial Fibrillation

By LabMedica International staff writers
Posted on 16 Nov 2021
Print article
Image: The BioMark HD real-time Polymerase Chain reaction (PCR) platform (Photo courtesy of Fluidigm)
Image: The BioMark HD real-time Polymerase Chain reaction (PCR) platform (Photo courtesy of Fluidigm)
Atrial fibrillation (AF) is associated with a five-fold increased risk of thromboembolisms, mainly stroke, independently of other risk factors. Accurate assessment to balance the risk of stroke and systemic embolic events (S/SEE), against the risk of major bleeding is therefore an important therapeutic goal in the clinical management of these patients.

Age, prior hemorrhage, severe renal disease, and anemia (hemoglobin) have been independently associated with an increased risk of major bleeding in patients with AF. The use of different combinations of these mainly clinical variables has resulted in at least five validated risk scores for better prediction of bleeding events in patients with AF.

Medical Scientists at Uppsala University (Uppsala, Sweden) explored associations between a wide range of biomarkers and bleeding risk in patients with AF on oral anticoagulants (OAC). Biomarkers were analyzed in a random sample of 4,200 patients, 204 cases with major bleedings. The replication cohort included 344 cases with major bleeding and 1,024 random controls.

The plasma concentrations of high-sensitivity cTnT-hs, NT-proBNP, and GDF-15 were determined by Roche immunoassays using a Cobas Analytics e601 (Roche Diagnostics, Rotkreuz, Switzerland). Interleukin 6 (IL-6) was analyzed using the high-sensitivity sandwich ELISA immunoassay (R&D Systems Inc, Minneapolis, MN, USA) and Cystatin C with the ARCHITECT system ci8200 (Abbott Laboratories, Abbott Park, IL, USA) using the particle-enhanced turbidimetric immunoassay (PETIA) from Gentian Diagnostics ASA (Moss, Norway).

The proteomic analyses were performed with the high-throughput Proximity Extension Assay (PEA) technique using the Target 96 Multiplex CVD II, CVD III, and Inflammation panels (Olink Proteomics, Uppsala, Sweden), which together simultaneously measured 276 selected proteins in plasma potentially related to CVD and inflammation. The PEA technology uses pairs of antibodies equipped with DNA reporter molecules When binding to their correct targets, antibody pairs give rise to new DNA amplicons each ID-barcoding their respective antigens. The amplicons are subsequently quantified using the Fluidigm BioMark HD real-time PCR platform (Fluidigm, South San Francisco, CA, USA).

The investigators reported that out of 268 proteins, nine biomarkers were independently associated with bleeding in both cohorts. In the replication cohort a significant linear hazard ratios per interquartile range were confirmed for these biomarkers: cytokine GDF-15, cTnT-hs, osteopontin (OPN), ephrin type-B receptor 4 (EphB4), TNF-R1, TNF-R2, soluble urokinase plasminogen activator receptor (suPAR), TRAIL-R2, and osteoprotegerin (OPG).

The authors concluded that in patients with AF on OAC, GDF-15, cTnT-hs, and seven novel biomarkers were independently associated with major bleedings and reflect pathophysiologic processes of inflammation, apoptosis, oxidative stress, vascular calcification, coagulation, and fibrinolysis. Investigations of the utility of these markers to refine risk stratification and guide the management of patients at high risk of bleeding are warranted. The study was published on the November 2021 issue of the Journal of Thrombosis and Haemostasis.

Related Links:
Uppsala University
Roche Diagnostics
R&D Systems
Abbott Laboratories
Gentian Diagnostics
Olink Proteomics

Gold Supplier
All-in-One Solution for All Molecular Testing
Laboratory Automation System
Lateral Flow Test Cassette Reader
Quantum Blue III
Gold Supplier
Desktop Urine Analyzer

Print article


Molecular Diagnostics

view channel
Image: Absence of nuclear immunohistochemical staining of MSH2 protein (A) and presence of MLH1 protein (B) in urothelial cell carcinoma of the urinary bladder of a patient carrying a germline MSH2 mutation. Observe the nuclear staining in stromal cells as an internal control (Photo courtesy of Radboud University Nijmegen Medical Centre)

Simple Urine Test Detects Urothelial Cancers in Lynch Syndrome Patients

Lynch Syndrome (LS) is an inherited genetic disorder that carries a high risk of cancer. LS is caused by mutations affecting MLH1, MSH2, MSH6 or PMS2 genes. More than one in 300 people have LS but most... Read more


view channel
Image: The Gazelle Hb Variant Test for screening, diagnosis and management of sickle cell disease and related hemoglobinopathies at the point of care (Photo courtesy of Hemex Health)

Point-of-Care Device Accurately Rapidly Diagnoses Sickle Cell Disease

Hemoglobinopathies are the most common autosomal hereditary disorders. Approximately 7% of the global population carries hemoglobin gene mutation including structural hemoglobin variants like sickle hemoglobin... Read more


view channel
Image: The IMMULITE 2000 XPi Immunoassay System provides multiple tests on a single, easy-to-use analyzer, including the thyroid-stimulating immunoglobulin assay (Photo courtesy of Siemens Healthcare)

Immunoassays Evaluated for Thyroid-Stimulating Receptor Antibody in Graves’ Disease

Graves' disease (GD), also known as toxic diffuse goiter, is an autoimmune disease that affects the thyroid. It frequently results in and is the most common cause of hyperthyroidism and it also often results... Read more


view channel
Image: The sciREADER CL2 enables high quality digital colorimetric imaging of various support formats (Photo courtesy of SCIENION)

Multiplex Immunoassay Developed for Confirmation and Typing of HTLV Infections

Human T-Cell Lymphotropic Viruses (HTLV) type 1 and type 2 account for an estimated five to 10 million infections worldwide and are transmitted through breast feeding, sexual contacts and contaminated... Read more


view channel

AI Accurately Detects and Diagnoses Colorectal Cancer from Tissue Scans As Well or Better Than Pathologists

Artificial intelligence (A) can accurately detect and diagnose colorectal cancer from tissue scans as well or better than pathologists, according to a new study. The study, which was conducted by researchers... Read more


view channel
Image: PKeye Workflow Monitor System (Photo courtesy of PerkinElmer, Inc.)

PerkinElmer’s New Cloud-Based Platform Enables Laboratory Personnel to Remotely Manage Its Instruments in Real-Time

PerkinElmer, Inc. (Waltham, MA; USA) has launched its PKeye Workflow Monitor, a cloud-based platform enabling laboratory personnel to remotely manage and monitor their PerkinElmer instruments and workflows... Read more


view channel

Global Point of Care Diagnostics Market to Top USD 35 Billion by 2027 Due to Rising Diabetic Cases

The global point of care diagnostics market is projected to grow at a CAGR of close to 6% from more than USD 23 billion in 2020 to over USD 35 billion by 2027, driven by an increase in the number of diabetic... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.